MINIDIAB

This brand name is authorized in Austria, Australia, Brazil, Hong Kong, New Zealand, Singapore, South Africa

Active ingredients

The drug MINIDIAB contains one active pharmaceutical ingredient (API):

1 Glipizide UNII X7WDT95N5C - GLIPIZIDE

Glipizide is an oral blood-glucose-lowering drug of the sulfonylurea class. The primary mode of action of glipizide is the stimulation of insulin secretion from the beta-cells of pancreatic islet tissue. Read about Glipizide

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
MINIDIAB Tablet	Pharmaceutical Benefits Scheme (AU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
A10BB07	Glipizide	A Alimentary tract and metabolism → A10 Drugs used in diabetes → A10B Blood glucose lowering drugs, excl. insulins → A10BB Sulfonamides, urea derivatives
Discover more medicines within A10BB07

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: AU	Pharmaceutical Benefits Scheme	Identifier(s): 2440K
Country: BR	Câmara de Regulação do Mercado de Medicamentos	Identifier(s): 522717110062517
Country: HK	Department of Health Drug Office	Identifier(s): 06976
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 2741
Country: SG	Health Sciences Authority	Identifier(s): 04059P
Country: ZA	Health Products Regulatory Authority	Identifier(s): L/21.2/248